June 29, 2020 / 1:05 PM / 15 days ago

BRIEF-Roche Announces Data For Treatment Of Haemophilia A

June 29 (Reuters) - Roche Holding AG:

* ROCHE ANNOUNCES NEW DATA AT ISTH 2020 CONGRESS, DEMONSTRATING ONGOING COMMITMENT TO ADVANCING CARE FOR PEOPLE WITH HAEMOPHILIA A

* SPARK THERAPEUTICS WILL PRESENT DATA FROM INITIAL DOSE COHORTS OF ITS PHASE I/II SPK-8011 GENE THERAPY STUDY

* SHOWING STABLE AND DURABLE FACTOR VIII EXPRESSION, SUBSTANTIAL IMPROVEMENT IN ANNUALISED BLEED RATE FOR MORE THAN TWO YEARS, AND AN ACCEPTABLE SAFETY PROFILE AFTER MORE THAN TWO YEARS OF FOLLOW-UP

* ROCHE WILL PRESENT SECOND INTERIM ANALYSIS RESULTS FROM PHASE IIIB STASEY STUDY

* REINFORCING SAFETY AND EFFICACY PROFILE OF HEMLIBRA IN PEOPLE WITH HAEMOPHILIA A WITH FACTOR VIII INHIBITORS SEEN IN PHASE III HAVEN STUDIES Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below